Monash Ivf Group Ltd · ASX:MVF

Monash Ivf — Shareholder Meeting (November 2019)

18 slides from Monash Ivf's shareholder meeting presentation, Nov 28, 2019

  1. Slide 1: Growing stronger together… 2019 Annual General Meeting

    Sample title Sample subtitle, you can add a custom image on the right by clicking the image icon Growing stronger together… 2019 Annual General Meeting 28 November 2019 1

  2. Slide 2: Disclaimer

    Disclaimer The presentation has been prepared by Monash IVF Group Limited (ACN 169 302 309) (“MVF”) (including its subsidiaries, affiliates and associated companies) and provides general background information about MVF’s activities as at the date of this presentation. The information does not purpo

  3. Slide 3: Chairman's address

    Chairman’s address Mr. Richard Davis MVF Group Annual General Meeting | 28 November 2019 3

  4. Slide 4: FY19 Key Achievements & Summary

    FY19 Key Achievements & Summary  Vision 2022 strategic roadmap developed, re-confirming our best-in- class Full Service positioning  MVF Australian Full Service Stimulated Cycles grew by 3.7% (excluding impact from departed specialist) New Picture  MVF ARS International growth continued as Stimul

  5. Slide 5: FY20 Trading Update and Outlook

    FY20 Trading Update and Outlook Trading Update  In Q1FY20, Stimulated Cycle market growth in our Key Markets grew by 2.4%;  In Q1FY20, MVF Australian Stimulated Cycles were inline with pcp however, the impact from doctor departures and general trading conditions has placed downward pressure on our

  6. Slide 6: Chairman's address Thank You

    Chairman’s address Thank You  The Company remains well positioned to optimise future earnings through strategic and operational momentum gained this calendar year;  I would like to thank our dedicated specialists, nurses, scientists and admin staff that have been integral to our performance and ac

  7. Slide 7: CEO Presentation

    CEO Presentation Mr. Michael Knaap MVF Group Annual General Meeting | 28 November 2019 7

  8. Slide 8: Overview of Monash IVF Group

    Overview of Monash IVF Group1 Monash IVF Group is a market leader in fertility ARS Diagnostic Ultrasound  23 clinics  2 specialised  18 clinics laboratories (VIC and  3 service centres SA)  16 Sonologists  90 Fertility Specialists  4 Australian states  2 day hospitals (SA &  7 Australian Ma

  9. Slide 9: FY19 Financial Summary

    FY19 Financial Summary Underlying FY19 NPAT decline of 2.3% after reporting 1H19 Underlying NPAT decline of 11.3% Underlying EBITDA Revenue EBITDA(1)(4) Margin% $152.0m $37.8m 24.9% FY18 $150.6m FY18 $38.1m FY18 25.3%  0.9%  0.8%  0.4% 2H19 $74.8m 2H19 $18.5m 2H19 24.7% ( 1.5%) ( 6.7%) ( 1.2%)

  10. Slide 10: ARS Australia - Operational Performance

    ARS Australia - Operational Performance Continued progress and investment to achieve our objectives and strategic initiatives  NIPGT internally developed, tested, patented and now commercially available exclusively across all MVF owned clinics  Trial commenced on an alternative method and technolo

  11. Slide 11: ARS Australia - Operational Performance (continued)

    ARS Australia - Operational Performance (continued) Continued investment to achieve objectives in our Strategic Roadmap  New Penrith clinic opened in October 2019 expanding our presence in NSW in the Greater Western region. We have additional consultation locations including Melbourne CBD, Brisbane

  12. Slide 12: Diagnostics Performance

    Diagnostics Performance We continue to build and broaden our Diagnostic capabilities and develop new technologies  Ultrasound scan volumes increased by 0.6% from 80,392 to 80,860  Sydney Ultrasound for Women (SUFW) scan volumes declined by 3.9% due to greater competitive pressures as a result of a

  13. Slide 13: ARS International Performance

    ARS International Performance ARS International continues to demonstrate exceptional growth with EBITDA up by 40.5%  Revenue increased by 32.3% from $8.77m to $11.60m as Stimulated Cycles increased by 21.8% from 849 to 1,034  The move to the new Facility in late 2017 has been the key driver of gro

  14. Slide 14: FY20 Strategy & Trading Update

    FY20 Strategy & Trading Update MVF Group Annual General Meeting | 28 November 2019 14

  15. Slide 15: MVF Group Annual General Meeting | 28 November 2019

    MVF Group Annual General Meeting | 28 November 2019 15

  16. Slide 16: FY20 Trading Update and Outlook

    FY20 Trading Update and Outlook Stimulated Cycle Key Markets1 Growth  Total Key Markets1 Stimulated Cycle market has grown by 2.4% during Q1FY20 as compared to prior corresponding 10.0% period, which is broadly in line with historical Industry long- 6.7% 6.3% 6.5% term growth rates; 4.7% 5.0% 2.8%

  17. Slide 17: FY20 Trading Update and Outlook

    FY20 Trading Update and Outlook Monash IVF Group remains well positioned to optimise future earnings through strategic and operational momentum gained over the last 12 months  Attraction of nine new fertility specialists during FY19 and a further three specialists in FY20 including an established f

  18. Slide 18: Growing stronger together…

    Sample title Sample subtitle, you can add a custom image on the right by clicking the image icon Growing stronger together… 18

Monash IVF Group — Shareholder Meeting (November 2019) on 6ix